STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Allenex (STO:ALNX) application to sell Olerup SSP products for HLA typing in Mexico has been approved. The application has been handled by Olerup local representative Biodist S.A. de C.V., a leading player in the Mexican HLA market. Sales begin immediately and the Mexican sales force is already trained on the new product line.
"Mexico is an important country for our geographical expansion and a priority in our growth strategy. We are also very pleased for having signed a distribution agreement with Biodist, since they are one of the leading distributors within transplant diagnostics in Mexico", Allenex CEO Anders Karlsson comments.
In Mexico a large proportion of sales occur through contracts within various health insurance schemes, and the right sales channels are therefore important in a product launch. The choice of Biodist gives Allenex the opportunity to collaborate with a partner that since many years is established in the important channels.
"We are very pleased to partner with Allenex and we look forward to sell their products. Biodist will include Olerup SSP products in contracts already for next year and this work will begin immediately. We also want to eventually include Allenex other products in the collaboration," says Rebeca Miramontes Vidal, CEO at Biodist.
Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on June 04, 2013, at 08.40 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.
This information was brought to you by Cision http://news.cision.com